GammaPod has obtained the CE mark

The certification of this innovative system for stereotactic breast radiation therapy paves the way for the first European installation and opens the door to installations at other centers.

"We are excited to bring GammaPod to the European market, where the need for more efficient and precise radiation therapy treatments for breast cancer is growing," said GammaPod’s inventor, Prof. Cedric Yu of the University of Maryland, who is also the founder and CEO of Xcision, the manufacturer of GammaPod, distributed in Italy by Tema Sinergie.

Watch how Cedric Yu describes the innovative technology for treating breast cancer

We are well aware that healthcare systems, in general, are increasingly prioritizing procedures that allow them to offer high-quality care at lower per-capita costs, while achieving high levels of patient satisfaction.

“GammaPod’s ability to deliver conformal radiation doses noninvasively and only to the tumor-affected area, with the precision and accuracy of stereotactic radiosurgery, will drastically reduce the number of treatment sessions and alleviate the discomfort patients experience from having to undergo prolonged treatments,” added Cedric Yu.

This perspective is also shared by Dr. Marco Trovò, Director of the Radiotherapy Department at ASUIUD in Udine, which will soon become the first European center to install GammaPod.

The CE marking, which allows for its marketing and use throughout Europe, is in fact a key element in making this first European installation a reality—a project agreed upon a year ago, when Dr. Marco Trovò explained the decision to invest in the revolutionary system developed by Xcision as follows:

“We chose GammaPod for its ability to change standard practice. In Italy and throughout Europe, our field is moving toward treating patients with early-stage breast cancer with shorter courses of radiation therapy. GammaPod is completely non-invasive and has the potential to allow our patients to receive a full course of treatment in just one to five sessions.

" ASUIUD will also join the GammaPod Research Consortium, founded by the University of Maryland School of Medicine (USA), to further explore GammaPod’s preoperative and postoperative applications. The goal is to identify new treatment options with higher doses and a reduced number of sessions. This would not only improve patients’ quality of life but also increase the number of patients who can be treated and reduce wait times.

"The ability to treat patients noninvasively with a single dose of radiation that removes the tumor and avoids surgery could revolutionize our field," says Dr. Trovò. "It would reduce the burden of treatment on patients while also lowering costs for the healthcare system."